Chemotherapy-induced periphreal neuropathy can affect patients' daily living, and some individuals may be more prone to it than others.
Chemotherapy-induced peripheral neuropathy (CIPN) is not only a bothersome symptom for patients being treated for cancer, but it also can significantly impact patients' daily lives, according to Grace Campbell, PhD, MSW, RN, CNL, CRRN, an assistant professor at the University of Pittsburgh School of Nursing.
Campbell discussed a recent pilot study of women with gynecologic cancer who were assessed before, during, and after chemotherapy treatment. Those who had an early onset of CIPN were more likely to report significant neuropathy that interfered with their daily lives by the end of their treatment.
FDA Grants Full Approval to Mirvetuximab Soravtansine for Pretreated Gynecologic Cancers
March 22nd 2024Mirvetuximab soravtansine received full approval from the FDA for pretreated adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.